Noncontraceptive health benefits of intrauterine devices: A systematic review

Obstetrical and Gynecological Survey

Volumn 57, Issue 2, 2002, Pages 120-128

  Hubacher, David ^a   Grimes, David A ^b,c  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b Biomedical Affairs   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER INTRAUTERINE DEVICE; LEVONORGESTREL; PLASTIC; TAMOXIFEN;

ANEMIA; ENDOMETRIUM CANCER; HORMONE SUBSTITUTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MENORRHAGIA; REVIEW; UTERUS BLEEDING;

ENDOMETRIAL NEOPLASMS; FEMALE; GENITAL DISEASES, FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INTRAUTERINE DEVICES; INTRAUTERINE DEVICES, COPPER; LEVONORGESTREL; PREGNANCY; PROGESTERONE CONGENERS;

EID: 0036163261     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006254-200202000-00024     Document Type: Review

References (72)

1. Health benefits of oral contraceptives
2. Noncontraceptive benefits of oral contraceptives
3. Noncontraceptive health benefits of oral steroidal contraceptives
4. Noncontraceptive effects of hormonal contraceptives: Bone mass, sexually transmitted disease and pelvic inflammatory disease, cardiovascular disease, menstrual function, and future fertility
5. IUDs: An update
6. Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C
7. Prolonged intrauterine contraception: A seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the copper T380 Ag IUDS
8. The levonorgestrel intrauterine system: Therapeutic aspects
9. The levonorgestrel-releasing intrauterine device: A wider role than contraception
10. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties
11. The medical review article revisited: Has the science improved?
12. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico
13. Intrauterine device use and endometrial cancer risk
14. Endometrial cancer in relation to intra-uterine device use
15. Intrauterine devices and endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives
16. Intrauterine device use and risk of endometrial cancer
17. Intrauterine contraception and the risk of endometrial cancer
18. A population-based case-control study of endometrial cancer in Shanghai, China
19. Tubal sterilization and use of an IUD and risk of cervical cancer
20. Use of intrauterine device and risk of invasive cervical cancer
21. Invasive cervical cancer and intrauterine device use
22. Epidemiology of endometriosis among parous women
23. Contraceptive methods and risk of pelvic endometriosis
24. Endometriosis in Lebanon: A case-control study
25. Prevalence and genesis of endometriosis
26. Is a long period without childbirth a risk factor for developing endometriosis?
27. Contraception: A risk factor for endometriosis
28. Epidemiology of endometriosis in women attending family planning clinics
29. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: A randomized comparative trial
30. Protective effect of intrauterine release of levonorgestrel on pelvic infection: Three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices
31. The incidence of actinomyces-like organisms in Papanicolaou-stained smears of copper- and levonorgestrel-releasing intrauterine devices
32. Health effects of long-term use of the intrauterine levonorgestrel- releasing system. A follow-up study over 12 years of continuous use
33. Two years of intrauterine contraception with levonorgestrel and with copper: A randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices
34. Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection
35. Prospective comparison study of levonorgestrel IUD versus Roller-Ball endometrial ablation in the management of refractory recurrent hypermenorrhea
36. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia
37. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy
38. The levonorgestrel intrauterine system in the management of menorrhagia
39. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding
40. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: Efficacy versus acceptability
41. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel- releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia
42. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia
43. Determiniation of menstrual blood loss
44. A rapid method of measuring menstrual blood loss using automatic extraction
45. Assessment of menstrual blood loss using a pictorial chart
46. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: A randomised trial
47. Intrauterine therapy with levonorgestrel releasing IUD of women with hypermenorrhea secondary to uterine fibroids
48. Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient
49. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel- releasing intrauterine device
50. The role of the levonorgestrel intrauterine device in the prevention and treatment of iron deficiency anemia during fertility regulation
51. A comparison of the effect of estrogen with or without progesterone on mood and physical symptoms in postmenopausal women
52. Intrauterine administration of levonorgestrel 5 and 10 μg/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year
53. Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy
54. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: Clinical and endometrial responses
55. Intrauterine release of levonorgestrel - A new way of adding progestogen in hormone replacement therapy
56. The levonorgestrel intrauterine system in menopausal hormone replacement therapy: Five-year experience
57. Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy
58. Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy
59. Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy
60. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: A randomised controlled trial
61. Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development
62. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives
63. The medical review article: State of the science
64. Systematic reviews: Synthesis of best evidence for clinical decisions
65. Publication bias: The problem that won't go away
66. U.S. women's perceptions of and attitudes about the IUD
67. Pill and IUD discontinuation in the United States, 1970-1975: The influence of the media
68. Time to pardon the IUD?
69. The intrauterine device: Still misunderstood after all these years
70. Intrauterine devices. The optimal long-term contraceptive method?
71. The intrauterine contraceptive device: An often-forgotten and maligned method of contraception